Association of natriuretic peptides and receptor activity with cardio-metabolic health at middle age.
ANP
BNP
CNP
Causal mediation analysis
NPR1
cGMP
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 04 2024
30 04 2024
Historique:
received:
22
02
2024
accepted:
25
04
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
Natriuretic peptides (NP) have multiple actions benefitting cardiovascular and metabolic health. Although many of these are mediated by Guanylyl Cyclase (GC) receptors NPR1 and NPR2, their role and relative importance in vivo is unclear. The intracellular mediator of NPR1 and NPR2, cGMP, circulates in plasma and can be used to examine relationships between receptor activity and tissue responses targeted by NPs. Plasma cGMP was measured in 348 participants previously recruited in a multidisciplinary community study (CHALICE) at age 50 years at a single centre. Associations between bio-active NPs and bio-inactive aminoterminal products with cGMP, and of cGMP with tissue response, were analysed using linear regression. Mediation of associations by NPs was assessed by Causal Mediation Analysis (CMA). ANP's contribution to cGMP far exceed those of other NPs. Modelling across three components (demographics, NPs and cardiovascular function) shows that ANP and CNP are independent and positive predictors of cGMP. Counter intuitively, findings from CMA imply that in specific tissues, NPR1 responds more to BNP stimulation than ANP. Collectively these findings align with longer tissue half-life of BNP, and direct further therapeutic interventions towards extending tissue activity of ANP and CNP.
Identifiants
pubmed: 38689031
doi: 10.1038/s41598-024-60677-4
pii: 10.1038/s41598-024-60677-4
doi:
Substances chimiques
Receptors, Atrial Natriuretic Factor
EC 4.6.1.2
Cyclic GMP
H2D2X058MU
atrial natriuretic factor receptor A
EC 4.6.1.2
atrial natriuretic factor receptor B
EC 4.6.1.2
Natriuretic Peptides
0
Atrial Natriuretic Factor
85637-73-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9919Subventions
Organisme : National Heart Foundation of New Zealand
ID : 1939
Organisme : Lottery Health Research
ID : R-LHR2022185112
Informations de copyright
© 2024. The Author(s).
Références
Kuhn, M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol. Rev. 96, 751–804. https://doi.org/10.1152/physrev.00022.2015 (2016).
doi: 10.1152/physrev.00022.2015
pubmed: 27030537
Hunt, P. J. et al. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am. J. Physiol. 269, R1397-1403 (1995).
pubmed: 8594942
Hunt, P. J., Richards, A. M., Espiner, E. A., Nicholls, M. G. & Yandle, T. G. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 78, 1428–1435 (1994).
pubmed: 8200946
Castro, L. R., Verde, I., Cooper, D. M. & Fischmeister, R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113, 2221–2228. https://doi.org/10.1161/CIRCULATIONAHA.105.599241 (2006).
doi: 10.1161/CIRCULATIONAHA.105.599241
pubmed: 16651469
pmcid: 1877795
Shotan, A. et al. Plasma cyclic guanosine monophosphate in chronic heart failure: Hemodynamic and neurohormonal correlations and response to nitrate therapy. Clin. Pharmacol. Ther. 54, 638–644. https://doi.org/10.1038/clpt.1993.201 (1993).
doi: 10.1038/clpt.1993.201
pubmed: 7903916
Persoon, S. et al. Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy. Heart Vessels 33, 948–957. https://doi.org/10.1007/s00380-018-1149-x (2018).
doi: 10.1007/s00380-018-1149-x
pubmed: 29546540
Hunt, P. J., Espiner, E. A., Nicholls, M. G., Richards, A. M. & Yandle, T. G. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J. Clin. Endocrinol. Metab. 81, 3871–3876. https://doi.org/10.1210/jcem.81.11.8923831 (1996).
doi: 10.1210/jcem.81.11.8923831
pubmed: 8923831
Moyes, A. J. & Hobbs, A. J. C-type natriuretic peptide: A multifaceted paracrine regulator in the heart and vasculature. Int. J. Mol. Sci. 20, 2281. https://doi.org/10.3390/ijms20092281 (2019).
doi: 10.3390/ijms20092281
pubmed: 31072047
pmcid: 6539462
Matsuo, A., Nagai-Okatani, C., Nishigori, M., Kangawa, K. & Minamino, N. Natriuretic peptides in human heart: Novel insight into their molecular forms, functions, and diagnostic use. Peptides 111, 3–17. https://doi.org/10.1016/j.peptides.2018.08.006 (2019).
doi: 10.1016/j.peptides.2018.08.006
pubmed: 30120963
Prickett, T. C. R. et al. Contrasting signals of cardiovascular health among natriuretic peptides in subjects without heart disease. Sci. Rep. 1, 12108 (2019).
doi: 10.1038/s41598-019-48553-y
Prickett, T. C. R., Pearson, J. F., Troughton, R. W., Kennedy, M. A. & Espiner, E. A. The predictive value of A, B, and C-type natriuretic peptides in people at risk of heart disease: Protocol for a longitudinal observational study. JMIR Res. Protoc. 12, e37011. https://doi.org/10.2196/37011 (2023).
doi: 10.2196/37011
pubmed: 36630163
pmcid: 9878369
Michel, K. et al. C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness. JCI Insight 5, 22. https://doi.org/10.1172/jci.insight.139910 (2020).
doi: 10.1172/jci.insight.139910
Werner, F. et al. Ablation of C-type natriuretic peptide/cGMP signaling in fibroblasts exacerbates adverse cardiac remodeling in mice. JCI Insight https://doi.org/10.1172/jci.insight.160416 (2023).
doi: 10.1172/jci.insight.160416
pubmed: 37227779
pmcid: 10371345
Bennett, B. D. et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol. Chem. 266, 23060–23067 (1991).
doi: 10.1016/S0021-9258(18)54463-X
pubmed: 1660465
Lewis, L. K., Raudsepp, S. D., Yandle, T. G., Prickett, T. C. & Richards, A. M. Development of a BNP1-32 immunoassay that does not cross-react with proBNP. Clin. Chem. 63, 1110–1117. https://doi.org/10.1373/clinchem.2016.269712 (2017).
doi: 10.1373/clinchem.2016.269712
pubmed: 28428353
Arnal, J. F., el Amrani, A. I. & Michel, J. B. Atrial natriuretic factor influences in vivo plasma, lung and aortic wall cGMP concentrations differently. Eur. J. Pharmacol. 237, 265–273. https://doi.org/10.1016/0014-2999(93)90278-p (1993).
doi: 10.1016/0014-2999(93)90278-p
pubmed: 8396039
Miyashita, K. et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58, 2880–2892. https://doi.org/10.2337/db09-0393 (2009).
doi: 10.2337/db09-0393
pubmed: 19690065
pmcid: 2780866
Bordicchia, M. et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J. Clin. Invest. 122, 1022–1036. https://doi.org/10.1172/JCI59701 (2012).
doi: 10.1172/JCI59701
pubmed: 22307324
pmcid: 3287224
Smith, M. W., Espiner, E. A., Yandle, T. G., Charles, C. J. & Richards, A. M. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J. Endocrinol. 167, 239–246. https://doi.org/10.1677/joe.0.1670239 (2000).
doi: 10.1677/joe.0.1670239
pubmed: 11054637
Bordicchia, M. et al. Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: A metabolic link with the cardiac natriuretic pathway. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311, R104-114. https://doi.org/10.1152/ajpregu.00499.2015 (2016).
doi: 10.1152/ajpregu.00499.2015
pubmed: 27101299
Standeven, K. F. et al. Neprilysin, obesity and the metabolic syndrome. Int. J. Obes. (Lond.) 35, 1031–1040. https://doi.org/10.1038/ijo.2010.227 (2011).
doi: 10.1038/ijo.2010.227
pubmed: 21042321
Martel, G., Hamet, P. & Tremblay, J. GREBP, a cGMP-response element-binding protein repressing the transcription of natriuretic peptide receptor 1 (NPR1/GCA). J. Biol. Chem. 285, 20926–20939. https://doi.org/10.1074/jbc.M109.061622 (2010).
doi: 10.1074/jbc.M109.061622
pubmed: 20444705
pmcid: 2898340
Terada, Y., Tomita, K., Nonoguchi, H., Yang, T. & Marumo, F. PCR localization of C-type natriuretic peptide and B-type receptor mRNAs in rat nephron segments. Am. J. Physiol. 267, F215-222. https://doi.org/10.1152/ajprenal.1994.267.2.F215 (1994).
doi: 10.1152/ajprenal.1994.267.2.F215
pubmed: 8067381
Buchner, S. et al. Left atrial size by planimetry is superior to M-mode diameter: Biochemical calibration by atrial and brain natriuretic peptide. J. Am. Soc. Echocardiogr. 21, 380–385. https://doi.org/10.1016/j.echo.2007.06.006 (2008).
doi: 10.1016/j.echo.2007.06.006
pubmed: 17681726
Sayed, N. et al. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nat. Aging 1, 598–615 (2021).
doi: 10.1038/s43587-021-00082-y
pubmed: 34888528
pmcid: 8654267
Szaroszyk, M. et al. Skeletal muscle derived Musclin protects the heart during pathological overload. Nat. Commun. 13, 149. https://doi.org/10.1038/s41467-021-27634-5 (2022).
doi: 10.1038/s41467-021-27634-5
pubmed: 35013221
pmcid: 8748430
Ibrahim, N. E. et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J. Am. Coll. Cardiol. 73, 1273–1284. https://doi.org/10.1016/j.jacc.2018.12.063 (2019).
doi: 10.1016/j.jacc.2018.12.063
pubmed: 30898202
Murphy, S. P. et al. Atrial natriuretic peptide and treatment with sacubitril/valsartan in heart failure with reduced ejection fraction. JACC Heart Fail. 9, 127–136. https://doi.org/10.1016/j.jchf.2020.09.013 (2021).
doi: 10.1016/j.jchf.2020.09.013
pubmed: 33189632
Tsutamoto, T. et al. Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure. Circulation 90, 823–829. https://doi.org/10.1161/01.cir.90.2.823 (1994).
doi: 10.1161/01.cir.90.2.823
pubmed: 8044954
Kielstein, J. T. et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109, 172–177. https://doi.org/10.1161/01.CIR.0000105764.22626.B1 (2004).
doi: 10.1161/01.CIR.0000105764.22626.B1
pubmed: 14662708
Mishra, S. et al. Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice. J. Clin. Invest. 131, 21. https://doi.org/10.1172/JCI148798 (2021).
doi: 10.1172/JCI148798
Scott, N. J. A., Rademaker, M. T., Charles, C. J., Espiner, E. A. & Richards, A. M. Hemodynamic, hormonal, and renal actions of phosphodiesterase-9 inhibition in experimental heart failure. J. Am. Coll. Cardiol. 74, 889–901. https://doi.org/10.1016/j.jacc.2019.05.067 (2019).
doi: 10.1016/j.jacc.2019.05.067
pubmed: 31416533
Qian, J. Y. et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ. Res. 91, 1063–1069 (2002).
doi: 10.1161/01.RES.0000043631.25915.E6
pubmed: 12456493
Korshunov, V. A. et al. Natriuretic peptide receptor 2 locus contributes to carotid remodeling. J. Am. Heart Assoc. 9, e014257. https://doi.org/10.1161/JAHA.119.014257 (2020).
doi: 10.1161/JAHA.119.014257
pubmed: 32394795
pmcid: 7660849
Spiranec, K. et al. Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure. Circulation 138, 494–508. https://doi.org/10.1161/CIRCULATIONAHA.117.033383 (2018).
doi: 10.1161/CIRCULATIONAHA.117.033383
pubmed: 29626067
Ying, W. et al. Associations between the cyclic guanosine monophosphate pathway and cardiovascular risk factors: MESA. J. Am. Heart Assoc. 8, e013149. https://doi.org/10.1161/JAHA.119.013149 (2019).
doi: 10.1161/JAHA.119.013149
pubmed: 31838972
pmcid: 6951064
Wehmann, R. E., Blonde, L. & Steiner, A. L. Sources of cyclic nucleotides in plasma. J. Clin. Invest. 53, 173–179. https://doi.org/10.1172/JCI107535 (1974).
doi: 10.1172/JCI107535
pubmed: 4357611
pmcid: 301451
Ma, X. et al. Evidence for angiotensin II as a naturally existing suppressor for the guanylyl cyclase a receptor and cyclic GMP generation. Int. J. Mol. Sci. 24, 8547. https://doi.org/10.3390/ijms24108547 (2023).
doi: 10.3390/ijms24108547
pubmed: 37239899
pmcid: 10218449
Krawutschke, C., Koesling, D. & Russwurm, M. Cyclic GMP in vascular relaxation: Export is of similar importance as degradation. Arterioscler. Thromb. Vasc. Biol. 35, 2011–2019. https://doi.org/10.1161/ATVBAHA.115.306133 (2015).
doi: 10.1161/ATVBAHA.115.306133
pubmed: 26205960
Schluter, P. J. et al. Canterbury Health, Ageing and Life Course (CHALICE) study: Rationale, design and methodology. N. Z. Med. J. 126, 71–85 (2013).
pubmed: 23824026
Olney, R. C., Permuy, J. W., Prickett, T. C., Han, J. C. & Espiner, E. A. Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children. Clin. Endocrinol. (Oxf.) 77, 416–422. https://doi.org/10.1111/j.1365-2265.2012.04392.x (2012).
doi: 10.1111/j.1365-2265.2012.04392.x
pubmed: 22435455
Palmer, S. C., Prickett, T. C., Espiner, E. A., Yandle, T. G. & Richards, A. M. Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 54, 612–618 (2009).
doi: 10.1161/HYPERTENSIONAHA.109.135608
pubmed: 19620509
Yandle, T. G., Espiner, E. A., Nicholls, M. G. & Duff, H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J. Clin. Endocrinol. Metab. 63, 72–79 (1986).
doi: 10.1210/jcem-63-1-72
pubmed: 2940257
Steiner, A. L., Wehmann, R. E., Parker, C. W. & Kipnis, D. M. Radioimmunoassay for the measurement of cyclic nucleotides. Adv. Cyclic Nucleotide Res. 2, 51–61 (1972).
pubmed: 4352296
Tingley, D., Yamamoto, T., Hirose, K., Keele, L. & Imai, K. mediation: R package for causal mediation analysis. J. Stat. Softw. 59, 5 (2014).
doi: 10.18637/jss.v059.i05